A Safety, Tolerability, Pharmacokinetic, and Pilot Food Effect Study of Single- and Multiple-Ascending Doses of LY3526318 in Healthy Participants
Latest Information Update: 23 Apr 2020
Price :
$35 *
At a glance
- Drugs LY 3526318 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 21 Apr 2020 Status changed from recruiting to discontinued.
- 16 Mar 2020 Planned End Date changed from 31 Mar 2020 to 7 Apr 2020.
- 16 Mar 2020 Planned primary completion date changed from 31 Mar 2020 to 7 Apr 2020.